Report Detail

Pharma & Healthcare Global Mumps Vaccine Market Research Report 2022

  • RnM4454469
  • |
  • 16 June, 2022
  • |
  • Global
  • |
  • 112 Pages
  • |
  • QYResearch
  • |
  • Pharma & Healthcare

The MMR vaccine is a vaccine against measles, mumps, and rubella (German measles). The first dose is generally given to children around 9 months to 15 months of age, with a second dose at 15 months to 6 years of age, with at least 4 weeks between the doses.
Industry Insights

Due to the COVID-19 pandemic, the global Mumps Vaccine market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Mumps Vaccine market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Mumps Vaccine landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.

Child accounting for % of the Mumps Vaccine global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospitals Pharmacies segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.

The global major manufacturers of Mumps Vaccine include MedImmune, Johnson & Johnson, Merck & Co., Inc., Sanofi, Serum Institute of India, Bavarian Nordic, Astellas Pharma India, CSL Limited and Emergent BioSolutions, etc. In terms of revenue, the global 3 largest players have a % market share of Mumps Vaccine in 2021.

This report focuses on Mumps Vaccine volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Mumps Vaccine market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and India, etc.

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Post-covid-19 Outlook

The readers in the section will understand how the Mumps Vaccine market scenario changed across the globe during the pandemic and post-pandemic. The study is done keeping in view the changes in aspects such as sales, demand and supply chain. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Segmental Outlook

Key segments including type and application have been elaborated in this report. The consultants at QY Research have studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and application during the historical period (2017-2022) and forecast period (2023-2028).

Segment by Type

Child

Adult

Segment by Application

Hospitals Pharmacies

Retail Pharmacies

Regional Outlook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2017-2028. This information derived through comprehensive research will help the reader to get familiar with the potential value of the investment in a particular region.

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Indonesia

Thailand

Malaysia

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Competitive Scenario

In this section, the readers will gain an understanding of the key players competing. The experts at QY Research have studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

MedImmune

Johnson & Johnson

Merck & Co., Inc.

Sanofi

Serum Institute of India

Bavarian Nordic

Astellas Pharma India

CSL Limited

Emergent BioSolutions

GlaxoSmithKline

Panacea Biotec, Ltd.

Biological E Limited

Bharat Biotech Ltd.

Novavax, Inc.

Novartis

Sinovac Biotech, Ltd.

Incepta Vaccine Limited

Valneva SE

VBI Vaccines

PT Bio Farma

Frequently Asked Questions

Which product segment grabbed the largest share in the Mumps Vaccine market?

How is the competitive scenario of the Mumps Vaccine market?

Which are the key factors aiding the Mumps Vaccine market growth?

Which are the prominent players in the Mumps Vaccine market?

Which region holds the maximum share in the Mumps Vaccine market?

What will be the CAGR of the Mumps Vaccine market during the forecast period?

Which application segment emerged as the leading segment in the Mumps Vaccine market?

What key trends are likely to emerge in the Mumps Vaccine market in the coming years?

What will be the Mumps Vaccine market size by 2028?

Which company held the largest share in the Mumps Vaccine market?


1 Mumps Vaccine Market Overview

  • 1.1 Product Overview and Scope of Mumps Vaccine
  • 1.2 Mumps Vaccine Segment by Type
  • 1.2.1 Global Mumps Vaccine Sales Growth Rate Comparison by Type (2022-2028)
  • 1.2.2 Child
  • 1.2.3 Adult
  • 1.3 Mumps Vaccine Segment by Application
  • 1.3.1 Global Mumps Vaccine Sales Comparison by Application: (2022-2028)
  • 1.3.2 Hospitals Pharmacies
  • 1.3.3 Retail Pharmacies
  • 1.4 Global Mumps Vaccine Market Size Estimates and Forecasts
  • 1.4.1 Global Mumps Vaccine Revenue 2017-2028
  • 1.4.2 Global Mumps Vaccine Sales 2017-2028
  • 1.4.3 Mumps Vaccine Market Size by Region: 2017 Versus 2021 Versus 2028
  • 2 Mumps Vaccine Market Competition by Manufacturers

    • 2.1 Global Mumps Vaccine Sales Market Share by Manufacturers (2017-2022)
    • 2.2 Global Mumps Vaccine Revenue Market Share by Manufacturers (2017-2022)
    • 2.3 Global Mumps Vaccine Average Price by Manufacturers (2017-2022)
    • 2.4 Manufacturers Mumps Vaccine Manufacturing Sites, Area Served, Product Type
    • 2.5 Mumps Vaccine Market Competitive Situation and Trends
    • 2.5.1 Mumps Vaccine Market Concentration Rate
  • 2.5.2 The Global Top 5 and Top 10 Largest Mumps Vaccine Players Market Share by Revenue
  • 2.5.3 Global Mumps Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
  • 3 Mumps Vaccine Retrospective Market Scenario by Region

    • 3.1 Global Mumps Vaccine Retrospective Market Scenario in Sales by Region: 2017-2022
    • 3.2 Global Mumps Vaccine Retrospective Market Scenario in Revenue by Region: 2017-2022
    • 3.3 North America Mumps Vaccine Market Facts & Figures by Country
    • 3.3.1 North America Mumps Vaccine Sales by Country
  • 3.3.2 North America Mumps Vaccine Revenue by Country
  • 3.3.3 United States
  • 3.3.4 Canada
  • 3.4 Europe Mumps Vaccine Market Facts & Figures by Country
  • 3.4.1 Europe Mumps Vaccine Sales by Country
  • 3.4.2 Europe Mumps Vaccine Revenue by Country
  • 3.4.3 Germany
  • 3.4.4 France
  • 3.4.5 U.K.
  • 3.4.6 Italy
  • 3.4.7 Russia
  • 3.5 Asia Pacific Mumps Vaccine Market Facts & Figures by Region
  • 3.5.1 Asia Pacific Mumps Vaccine Sales by Region
  • 3.5.2 Asia Pacific Mumps Vaccine Revenue by Region
  • 3.5.3 China
  • 3.5.4 Japan
  • 3.5.5 South Korea
  • 3.5.6 India
  • 3.5.7 Australia
  • 3.5.8 China Taiwan
  • 3.5.9 Indonesia
  • 3.5.10 Thailand
  • 3.5.11 Malaysia
  • 3.6 Latin America Mumps Vaccine Market Facts & Figures by Country
  • 3.6.1 Latin America Mumps Vaccine Sales by Country
  • 3.6.2 Latin America Mumps Vaccine Revenue by Country
  • 3.6.3 Mexico
  • 3.6.4 Brazil
  • 3.6.5 Argentina
  • 3.7 Middle East and Africa Mumps Vaccine Market Facts & Figures by Country
  • 3.7.1 Middle East and Africa Mumps Vaccine Sales by Country
  • 3.7.2 Middle East and Africa Mumps Vaccine Revenue by Country
  • 3.7.3 Turkey
  • 3.7.4 Saudi Arabia
  • 3.7.5 UAE
  • 4 Global Mumps Vaccine Historic Market Analysis by Type

    • 4.1 Global Mumps Vaccine Sales Market Share by Type (2017-2022)
    • 4.2 Global Mumps Vaccine Revenue Market Share by Type (2017-2022)
    • 4.3 Global Mumps Vaccine Price by Type (2017-2022)

    5 Global Mumps Vaccine Historic Market Analysis by Application

    • 5.1 Global Mumps Vaccine Sales Market Share by Application (2017-2022)
    • 5.2 Global Mumps Vaccine Revenue Market Share by Application (2017-2022)
    • 5.3 Global Mumps Vaccine Price by Application (2017-2022)

    6 Key Companies Profiled

    • 6.1 MedImmune
    • 6.1.1 MedImmune Corporation Information
  • 6.1.2 MedImmune Description and Business Overview
  • 6.1.3 MedImmune Mumps Vaccine Sales, Revenue and Gross Margin (2017-2022)
  • 6.1.4 MedImmune Mumps Vaccine Product Portfolio
  • 6.1.5 MedImmune Recent Developments/Updates
  • 6.2 Johnson & Johnson
  • 6.2.1 Johnson & Johnson Corporation Information
  • 6.2.2 Johnson & Johnson Description and Business Overview
  • 6.2.3 Johnson & Johnson Mumps Vaccine Sales, Revenue and Gross Margin (2017-2022)
  • 6.2.4 Johnson & Johnson Mumps Vaccine Product Portfolio
  • 6.2.5 Johnson & Johnson Recent Developments/Updates
  • 6.3 Merck & Co., Inc.
  • 6.3.1 Merck & Co., Inc. Corporation Information
  • 6.3.2 Merck & Co., Inc. Description and Business Overview
  • 6.3.3 Merck & Co., Inc. Mumps Vaccine Sales, Revenue and Gross Margin (2017-2022)
  • 6.3.4 Merck & Co., Inc. Mumps Vaccine Product Portfolio
  • 6.3.5 Merck & Co., Inc. Recent Developments/Updates
  • 6.4 Sanofi
  • 6.4.1 Sanofi Corporation Information
  • 6.4.2 Sanofi Description and Business Overview
  • 6.4.3 Sanofi Mumps Vaccine Sales, Revenue and Gross Margin (2017-2022)
  • 6.4.4 Sanofi Mumps Vaccine Product Portfolio
  • 6.4.5 Sanofi Recent Developments/Updates
  • 6.5 Serum Institute of India
  • 6.5.1 Serum Institute of India Corporation Information
  • 6.5.2 Serum Institute of India Description and Business Overview
  • 6.5.3 Serum Institute of India Mumps Vaccine Sales, Revenue and Gross Margin (2017-2022)
  • 6.5.4 Serum Institute of India Mumps Vaccine Product Portfolio
  • 6.5.5 Serum Institute of India Recent Developments/Updates
  • 6.6 Bavarian Nordic
  • 6.6.1 Bavarian Nordic Corporation Information
  • 6.6.2 Bavarian Nordic Description and Business Overview
  • 6.6.3 Bavarian Nordic Mumps Vaccine Sales, Revenue and Gross Margin (2017-2022)
  • 6.6.4 Bavarian Nordic Mumps Vaccine Product Portfolio
  • 6.6.5 Bavarian Nordic Recent Developments/Updates
  • 6.7 Astellas Pharma India
  • 6.6.1 Astellas Pharma India Corporation Information
  • 6.6.2 Astellas Pharma India Description and Business Overview
  • 6.6.3 Astellas Pharma India Mumps Vaccine Sales, Revenue and Gross Margin (2017-2022)
  • 6.4.4 Astellas Pharma India Mumps Vaccine Product Portfolio
  • 6.7.5 Astellas Pharma India Recent Developments/Updates
  • 6.8 CSL Limited
  • 6.8.1 CSL Limited Corporation Information
  • 6.8.2 CSL Limited Description and Business Overview
  • 6.8.3 CSL Limited Mumps Vaccine Sales, Revenue and Gross Margin (2017-2022)
  • 6.8.4 CSL Limited Mumps Vaccine Product Portfolio
  • 6.8.5 CSL Limited Recent Developments/Updates
  • 6.9 Emergent BioSolutions
  • 6.9.1 Emergent BioSolutions Corporation Information
  • 6.9.2 Emergent BioSolutions Description and Business Overview
  • 6.9.3 Emergent BioSolutions Mumps Vaccine Sales, Revenue and Gross Margin (2017-2022)
  • 6.9.4 Emergent BioSolutions Mumps Vaccine Product Portfolio
  • 6.9.5 Emergent BioSolutions Recent Developments/Updates
  • 6.10 GlaxoSmithKline
  • 6.10.1 GlaxoSmithKline Corporation Information
  • 6.10.2 GlaxoSmithKline Description and Business Overview
  • 6.10.3 GlaxoSmithKline Mumps Vaccine Sales, Revenue and Gross Margin (2017-2022)
  • 6.10.4 GlaxoSmithKline Mumps Vaccine Product Portfolio
  • 6.10.5 GlaxoSmithKline Recent Developments/Updates
  • 6.11 Panacea Biotec, Ltd.
  • 6.11.1 Panacea Biotec, Ltd. Corporation Information
  • 6.11.2 Panacea Biotec, Ltd. Mumps Vaccine Description and Business Overview
  • 6.11.3 Panacea Biotec, Ltd. Mumps Vaccine Sales, Revenue and Gross Margin (2017-2022)
  • 6.11.4 Panacea Biotec, Ltd. Mumps Vaccine Product Portfolio
  • 6.11.5 Panacea Biotec, Ltd. Recent Developments/Updates
  • 6.12 Biological E Limited
  • 6.12.1 Biological E Limited Corporation Information
  • 6.12.2 Biological E Limited Mumps Vaccine Description and Business Overview
  • 6.12.3 Biological E Limited Mumps Vaccine Sales, Revenue and Gross Margin (2017-2022)
  • 6.12.4 Biological E Limited Mumps Vaccine Product Portfolio
  • 6.12.5 Biological E Limited Recent Developments/Updates
  • 6.13 Bharat Biotech Ltd.
  • 6.13.1 Bharat Biotech Ltd. Corporation Information
  • 6.13.2 Bharat Biotech Ltd. Mumps Vaccine Description and Business Overview
  • 6.13.3 Bharat Biotech Ltd. Mumps Vaccine Sales, Revenue and Gross Margin (2017-2022)
  • 6.13.4 Bharat Biotech Ltd. Mumps Vaccine Product Portfolio
  • 6.13.5 Bharat Biotech Ltd. Recent Developments/Updates
  • 6.14 Novavax, Inc.
  • 6.14.1 Novavax, Inc. Corporation Information
  • 6.14.2 Novavax, Inc. Mumps Vaccine Description and Business Overview
  • 6.14.3 Novavax, Inc. Mumps Vaccine Sales, Revenue and Gross Margin (2017-2022)
  • 6.14.4 Novavax, Inc. Mumps Vaccine Product Portfolio
  • 6.14.5 Novavax, Inc. Recent Developments/Updates
  • 6.15 Novartis
  • 6.15.1 Novartis Corporation Information
  • 6.15.2 Novartis Mumps Vaccine Description and Business Overview
  • 6.15.3 Novartis Mumps Vaccine Sales, Revenue and Gross Margin (2017-2022)
  • 6.15.4 Novartis Mumps Vaccine Product Portfolio
  • 6.15.5 Novartis Recent Developments/Updates
  • 6.16 Sinovac Biotech, Ltd.
  • 6.16.1 Sinovac Biotech, Ltd. Corporation Information
  • 6.16.2 Sinovac Biotech, Ltd. Mumps Vaccine Description and Business Overview
  • 6.16.3 Sinovac Biotech, Ltd. Mumps Vaccine Sales, Revenue and Gross Margin (2017-2022)
  • 6.16.4 Sinovac Biotech, Ltd. Mumps Vaccine Product Portfolio
  • 6.16.5 Sinovac Biotech, Ltd. Recent Developments/Updates
  • 6.17 Incepta Vaccine Limited
  • 6.17.1 Incepta Vaccine Limited Corporation Information
  • 6.17.2 Incepta Vaccine Limited Mumps Vaccine Description and Business Overview
  • 6.17.3 Incepta Vaccine Limited Mumps Vaccine Sales, Revenue and Gross Margin (2017-2022)
  • 6.17.4 Incepta Vaccine Limited Mumps Vaccine Product Portfolio
  • 6.17.5 Incepta Vaccine Limited Recent Developments/Updates
  • 6.18 Valneva SE
  • 6.18.1 Valneva SE Corporation Information
  • 6.18.2 Valneva SE Mumps Vaccine Description and Business Overview
  • 6.18.3 Valneva SE Mumps Vaccine Sales, Revenue and Gross Margin (2017-2022)
  • 6.18.4 Valneva SE Mumps Vaccine Product Portfolio
  • 6.18.5 Valneva SE Recent Developments/Updates
  • 6.19 VBI Vaccines
  • 6.19.1 VBI Vaccines Corporation Information
  • 6.19.2 VBI Vaccines Mumps Vaccine Description and Business Overview
  • 6.19.3 VBI Vaccines Mumps Vaccine Sales, Revenue and Gross Margin (2017-2022)
  • 6.19.4 VBI Vaccines Mumps Vaccine Product Portfolio
  • 6.19.5 VBI Vaccines Recent Developments/Updates
  • 6.20 PT Bio Farma
  • 6.20.1 PT Bio Farma Corporation Information
  • 6.20.2 PT Bio Farma Mumps Vaccine Description and Business Overview
  • 6.20.3 PT Bio Farma Mumps Vaccine Sales, Revenue and Gross Margin (2017-2022)
  • 6.20.4 PT Bio Farma Mumps Vaccine Product Portfolio
  • 6.20.5 PT Bio Farma Recent Developments/Updates
  • 7 Mumps Vaccine Manufacturing Cost Analysis

    • 7.1 Mumps Vaccine Key Raw Materials Analysis
    • 7.1.1 Key Raw Materials
  • 7.1.2 Key Suppliers of Raw Materials
  • 7.2 Proportion of Manufacturing Cost Structure
  • 7.3 Manufacturing Process Analysis of Mumps Vaccine
  • 7.4 Mumps Vaccine Industrial Chain Analysis
  • 8 Marketing Channel, Distributors and Customers

    • 8.1 Marketing Channel
    • 8.2 Mumps Vaccine Distributors List
    • 8.3 Mumps Vaccine Customers

    9 Mumps Vaccine Market Dynamics

    • 9.1 Mumps Vaccine Industry Trends
    • 9.2 Mumps Vaccine Market Drivers
    • 9.3 Mumps Vaccine Market Challenges
    • 9.4 Mumps Vaccine Market Restraints

    10 Global Market Forecast

    • 10.1 Mumps Vaccine Market Estimates and Projections by Type
    • 10.1.1 Global Forecasted Sales of Mumps Vaccine by Type (2023-2028)
  • 10.1.2 Global Forecasted Revenue of Mumps Vaccine by Type (2023-2028)
  • 10.2 Mumps Vaccine Market Estimates and Projections by Application
  • 10.2.1 Global Forecasted Sales of Mumps Vaccine by Application (2023-2028)
  • 10.2.2 Global Forecasted Revenue of Mumps Vaccine by Application (2023-2028)
  • 10.3 Mumps Vaccine Market Estimates and Projections by Region
  • 10.3.1 Global Forecasted Sales of Mumps Vaccine by Region (2023-2028)
  • 10.3.2 Global Forecasted Revenue of Mumps Vaccine by Region (2023-2028)
  • 11 Research Finding and Conclusion

      12 Methodology and Data Source

      • 12.1 Methodology/Research Approach
      • 12.1.1 Research Programs/Design
    • 12.1.2 Market Size Estimation
    • 12.1.3 Market Breakdown and Data Triangulation
    • 12.2 Data Source
    • 12.2.1 Secondary Sources
    • 12.2.2 Primary Sources
    • 12.3 Author List
    • Summary:
      Get latest Market Research Reports on Mumps Vaccine. Industry analysis & Market Report on Mumps Vaccine is a syndicated market report, published as Global Mumps Vaccine Market Research Report 2022. It is complete Research Study and Industry Analysis of Mumps Vaccine market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

      Last updated on

      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $2,900.00
      $5,800.00
      2,317.10
      4,634.20
      2,705.70
      5,411.40
      451,095.00
      902,190.00
      241,657.00
      483,314.00
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report